<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242342</url>
  </required_header>
  <id_info>
    <org_study_id>RASTAF IRM</org_study_id>
    <nct_id>NCT04242342</nct_id>
  </id_info>
  <brief_title>Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors</brief_title>
  <acronym>RASTAF</acronym>
  <official_title>Phase II of Adaptative Magnetic Resonance-Guided Stereotactic Body Radiotherapy (SBRT) for Treatment of Primary or Secondary Progressive Liver Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic metastases are common in solid cancers (up to 30% of patients with colorectal cancer&#xD;
      and up to 50% of patients during their follow-up). The incidence of primary liver cancer&#xD;
      increases due to the increase in chronic liver diseases induced by excessive alcohol&#xD;
      consumption, hepatitis B and C viruses, and excess fat in the liver. Surgical excision of&#xD;
      these liver lesions is the reference treatment but it cannot always be realised.&#xD;
&#xD;
      Stereotactic radiotherapy is a recent technique proposed to hepatic metastases treatment from&#xD;
      solid cancers and primary hepatic lesions (HCC or cholangiocarcinomas); it is possible to&#xD;
      deliver high doses of radiation in the most conformational way possible in order to limit the&#xD;
      irradiation of the non-tumor liver. The results of this stereotactic radiotherapy are&#xD;
      currently very good with control rates of 75 to 80% at 1 and 2 years with acceptable rates of&#xD;
      severe toxicities of 10%. However, the fear of hepatic, digestive (colon, esophagus, stomach)&#xD;
      or even cardiac toxicities limits its using to the majority of patients because coupled with&#xD;
      a conventional scanner it do not allow direct visualization of the lesion.&#xD;
&#xD;
      Due to its non-irradiating nature, MRI guided stereotactic radiotherapy can generate&#xD;
      continuous imaging, during the irradiation session, offering &quot; in live &quot; a visualization of&#xD;
      the tumor target and organs at risk of proximity. In increasing the precision and safety in&#xD;
      the delivery of irradiation, it allows to hope for several areas for improvement of&#xD;
      treatment:&#xD;
&#xD;
        -  reduced uncertainty margins&#xD;
&#xD;
        -  an increase in the dose delivered&#xD;
&#xD;
        -  the accessibility of tumor lesions near sensitive organs (esophagus, stomach, heart&#xD;
           chambers, intestines, duodenum, right kidney).&#xD;
&#xD;
      More, this accelerator allows a re-optimization of the initial dosimetric plan to the&#xD;
      anatomical changes of the day to allow an MRI guided adaptive radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MRI guided stereotactic radiotherapy of hepatic lesions with an MRIdian® Linac tested in&#xD;
      this study will allow:&#xD;
&#xD;
        -  to see the tumor target in live with a non-irradiating imaging&#xD;
&#xD;
        -  a reduction of the volume of non-tumor liver irradiated at high doses&#xD;
&#xD;
        -  An progession of the dose delivered to the tumor lesion to allow tumor control to be&#xD;
           increased.&#xD;
&#xD;
        -  a new dosimetric plan adapted each day to the new contours to avoid a risk of severe&#xD;
           digestive toxicity while ensuring optimal treatment, at an appropriate dose, of the&#xD;
           tumor volume.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">November 26, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local control at 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>lack of progression according to RECIST criteria</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with a localized primary tumor (hepatocellular carcinoma or cholangiocarcinoma) or a secondary hepatic localization of a solid carcinoma, with one to three hepatic lesions accessible to a treatment by stereotactic radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adaptative MR-Guided Stereotactic Body Radiotherapy</intervention_name>
    <description>If lesion near organs at risk:&#xD;
Prescription of 50 Gy in 5 fractions of 10 Gy&#xD;
3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment&#xD;
If lesion far of organs at risk:&#xD;
Prescription of 60 Gy in 6 fractions of 10 Gy&#xD;
3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Man or woman aged 18 or over.&#xD;
&#xD;
          2. Performance Status 0 or 1.&#xD;
&#xD;
          3. Primary or secondary liver tumor(s)&#xD;
&#xD;
          4. maximum 1 to 3 liver tumor(s) accessible to stereotaxic body radiotherapy therapy.&#xD;
&#xD;
          5. ASAT and ALAT &lt;3 times the upper limit of normal,&#xD;
&#xD;
          6. Albuminemia ≥ 28g / L.&#xD;
&#xD;
          7. Creatinine clearance&gt; 30ml / min&#xD;
&#xD;
          8. signing of informed consent.&#xD;
&#xD;
          9. Woman of childbearing age who accepts effective contraception during the course of&#xD;
             treatment and within 3 months of treatment.&#xD;
&#xD;
         10. Patient affiliated to a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MRI contraindication&#xD;
&#xD;
          2. Pregnant or breastfeeding woman.&#xD;
&#xD;
          3. Patient with decompensated liver cirrhosis or cirrhosis&gt; Child B7&#xD;
&#xD;
          4. Patient previously irradiated in the planned treatment area.&#xD;
&#xD;
          5. Refusal of patient's consent.&#xD;
&#xD;
          6. Patient unable to give his consent, under guardianship or unable to submit to the&#xD;
             treatment protocol or protocol follow-up.&#xD;
&#xD;
          7. History of another malignant tumor except:&#xD;
&#xD;
               -  Malignant neoplasm treated with curative intent and with no known active disease&#xD;
                  ≥ 5 years before inclusion,&#xD;
&#xD;
               -  Non-melanoma or malignant lentigo skin cancer treated adequately without signs of&#xD;
                  disease,&#xD;
&#xD;
               -  Carcinoma in situ treated without sign of disease,&#xD;
&#xD;
               -  Prostate carcinoma that did not require curative treatment.&#xD;
&#xD;
          8. Known hypersensitivity to gadolinium or other gadolinium chelates.&#xD;
&#xD;
          9. Patient participating in another therapeutic trial which would require the&#xD;
             administration of experimental treatment during the period between inclusion and the&#xD;
             end of radiotherapy treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Magali Rouffiac Thouant</last_name>
    <phone>03 80 73 75 18</phone>
    <email>mrouffiac@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emlie REDERSTORFF</last_name>
    <phone>03 45 34 81 16</phone>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magalie ROUFFIAC</last_name>
      <phone>03 45 34 81 06</phone>
      <email>mrouffiac@cgfl.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie Rederstorff</last_name>
      <phone>03 45 34 81 16</phone>
      <email>erederstorff@cgfl.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

